BTG is
a global leader in patenting and marketing intellectual property rights (IPR) for
technologies that shape the future. BTG acquires, develops and licenses IPR covering
innovative products and
processes in the fields of electronics & telecommunications, biosciences and medical
& physical sciences.
With its headquarters in London and offices in Philadelphia and Tokyo, BTG capitalises on
a
global network of contacts in companies, universities and research institutions to
identify and commercialise the most promising technologies. Since its founding in 1949,
BTG has commercialised such major innovations as magnetic resonance imaging (MRI),
Interferon and wide-spectrum cephalosporin antibiotics. BTG is quoted on the London Stock
Exchange under the symbol “BGC”. |
